Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 6.71
KMDA's Cash to Debt is ranked lower than
61% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. KMDA: 6.71 )
Ranked among companies with meaningful Cash to Debt only.
KMDA' s 10-Year Cash to Debt Range
Min: 1.32  Med: 4.49 Max: N/A
Current: 6.71
Equity to Asset 0.69
KMDA's Equity to Asset is ranked higher than
50% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. KMDA: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
KMDA' s 10-Year Equity to Asset Range
Min: 0.28  Med: 0.62 Max: 0.69
Current: 0.69
0.28
0.69
F-Score: 3
Z-Score: 1.90
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -21.74
KMDA's Operating margin (%) is ranked higher than
60% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. KMDA: -21.74 )
Ranked among companies with meaningful Operating margin (%) only.
KMDA' s 10-Year Operating margin (%) Range
Min: -121.42  Med: -16.15 Max: 5.83
Current: -21.74
-121.42
5.83
Net-margin (%) -23.03
KMDA's Net-margin (%) is ranked higher than
59% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. KMDA: -23.03 )
Ranked among companies with meaningful Net-margin (%) only.
KMDA' s 10-Year Net-margin (%) Range
Min: -170.4  Med: -18.59 Max: 0.63
Current: -23.03
-170.4
0.63
ROE (%) -19.07
KMDA's ROE (%) is ranked higher than
58% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. KMDA: -19.07 )
Ranked among companies with meaningful ROE (%) only.
KMDA' s 10-Year ROE (%) Range
Min: -196.96  Med: -20.08 Max: 1.83
Current: -19.07
-196.96
1.83
ROA (%) -12.31
KMDA's ROA (%) is ranked higher than
61% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. KMDA: -12.31 )
Ranked among companies with meaningful ROA (%) only.
KMDA' s 10-Year ROA (%) Range
Min: -59.2  Med: -11.02 Max: 0.58
Current: -12.31
-59.2
0.58
ROC (Joel Greenblatt) (%) -34.20
KMDA's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. KMDA: -34.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KMDA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -111.83  Med: -13.79 Max: 26.66
Current: -34.2
-111.83
26.66
Revenue Growth (3Y)(%) -2.70
KMDA's Revenue Growth (3Y)(%) is ranked lower than
52% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. KMDA: -2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KMDA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.7  Med: 24.60 Max: 44.1
Current: -2.7
-2.7
44.1
» KMDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

KMDA Guru Trades in Q2 2014

Jim Simons 70,265 sh (+210.91%)
John Paulson 750,000 sh (unchged)
» More
Q3 2014

KMDA Guru Trades in Q3 2014

John Paulson 750,000 sh (unchged)
Jim Simons 67,740 sh (-3.59%)
» More
Q4 2014

KMDA Guru Trades in Q4 2014

Jim Simons 123,406 sh (+82.18%)
John Paulson 739,356 sh (-1.42%)
» More
Q1 2015

KMDA Guru Trades in Q1 2015

Jim Simons 169,100 sh (+37.03%)
John Paulson 739,356 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 26.88
KMDA's Forward P/E is ranked lower than
61% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. KMDA: 26.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.76
KMDA's P/B is ranked higher than
83% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. KMDA: 1.76 )
Ranked among companies with meaningful P/B only.
KMDA' s 10-Year P/B Range
Min: 1.41  Med: 5.07 Max: 11.31
Current: 1.76
1.41
11.31
P/S 2.02
KMDA's P/S is ranked higher than
88% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. KMDA: 2.02 )
Ranked among companies with meaningful P/S only.
KMDA' s 10-Year P/S Range
Min: 1.58  Med: 4.31 Max: 13.19
Current: 2.02
1.58
13.19
EV-to-EBIT -6.66
KMDA's EV-to-EBIT is ranked higher than
96% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. KMDA: -6.66 )
Ranked among companies with meaningful EV-to-EBIT only.
KMDA' s 10-Year EV-to-EBIT Range
Min: -173.6  Med: 52.80 Max: 591.1
Current: -6.66
-173.6
591.1
Current Ratio 3.29
KMDA's Current Ratio is ranked lower than
59% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. KMDA: 3.29 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s 10-Year Current Ratio Range
Min: 2.21  Med: 3.29 Max: 4.42
Current: 3.29
2.21
4.42
Quick Ratio 2.27
KMDA's Quick Ratio is ranked lower than
68% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. KMDA: 2.27 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s 10-Year Quick Ratio Range
Min: 1.45  Med: 2.47 Max: 3.59
Current: 2.27
1.45
3.59
Days Inventory 174.89
KMDA's Days Inventory is ranked lower than
69% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. KMDA: 174.89 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s 10-Year Days Inventory Range
Min: 34.72  Med: 125.92 Max: 187.18
Current: 174.89
34.72
187.18
Days Sales Outstanding 64.56
KMDA's Days Sales Outstanding is ranked lower than
52% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. KMDA: 64.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s 10-Year Days Sales Outstanding Range
Min: 69.61  Med: 89.95 Max: 97.76
Current: 64.56
69.61
97.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.89
KMDA's Price/Net Cash is ranked higher than
50% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. KMDA: 8.89 )
Ranked among companies with meaningful Price/Net Cash only.
KMDA' s 10-Year Price/Net Cash Range
Min: 9.82  Med: 14.21 Max: 25.84
Current: 8.89
9.82
25.84
Price/Net Current Asset Value 2.46
KMDA's Price/Net Current Asset Value is ranked higher than
88% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. KMDA: 2.46 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KMDA' s 10-Year Price/Net Current Asset Value Range
Min: 2.21  Med: 6.65 Max: 38.13
Current: 2.46
2.21
38.13
Price/Tangible Book 1.76
KMDA's Price/Tangible Book is ranked higher than
87% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. KMDA: 1.76 )
Ranked among companies with meaningful Price/Tangible Book only.
KMDA' s 10-Year Price/Tangible Book Range
Min: 1.61  Med: 5.05 Max: 9.99
Current: 1.76
1.61
9.99
Price/Median PS Value 0.46
KMDA's Price/Median PS Value is ranked higher than
91% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. KMDA: 0.46 )
Ranked among companies with meaningful Price/Median PS Value only.
KMDA' s 10-Year Price/Median PS Value Range
Min: 0.43  Med: 0.97 Max: 3.04
Current: 0.46
0.43
3.04
Earnings Yield (Greenblatt) (%) -15.00
KMDA's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. KMDA: -15.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KMDA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 1.00 Max: 2.6
Current: -15
0.2
2.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KMDA.Israel,
Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.
» More Articles for KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
Kamada Granted Key New Patent for Inhaled AAT and eFlow® Nebulizer System in Israel Jul 01 2015
Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the... Jun 23 2015
Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the... Jun 22 2015
Edited Transcript of KMDA.TA earnings conference call or presentation 12-May-15 12:30pm GMT Jun 17 2015
Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to... May 20 2015
Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to... May 20 2015
Kamada Reports First Quarter 2015 Financial Results May 12 2015
Kamada reports 1Q loss May 12 2015
Kamada reports 1Q loss May 12 2015
Kamada Reports First Quarter 2015 Financial Results May 12 2015
Kamada to Host First Quarter 2015 Financial Results Conference Call on May 12, 2015 May 10 2015
Kamada to Host First Quarter 2015 Financial Results Conference Call on May 12, 2015 May 08 2015
Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... May 06 2015
Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... May 06 2015
CFO Moves: E.ON, Yoox, AudioCodes, Kamada Apr 28 2015
Kamada Announces Executive Management Changes Apr 28 2015
Kamada Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... Apr 22 2015
Kamada Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... Apr 20 2015
Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary... Apr 01 2015
Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary... Apr 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK